AR102871A1 - Métodos de tratamiento de fibrosis - Google Patents
Métodos de tratamiento de fibrosisInfo
- Publication number
- AR102871A1 AR102871A1 ARP150103925A ARP150103925A AR102871A1 AR 102871 A1 AR102871 A1 AR 102871A1 AR P150103925 A ARP150103925 A AR P150103925A AR P150103925 A ARP150103925 A AR P150103925A AR 102871 A1 AR102871 A1 AR 102871A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment methods
- fibrosis treatment
- patient
- inhibitor
- fibrosis
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title abstract 2
- 230000004761 fibrosis Effects 0.000 title abstract 2
- 229940124291 BTK inhibitor Drugs 0.000 abstract 2
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 abstract 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 abstract 1
- 229960001507 ibrutinib Drugs 0.000 abstract 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002427 irreversible effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B31/00—Disazo and polyazo dyes of the type A->B->C, A->B->C->D, or the like, prepared by diazotising and coupling
- C09B31/02—Disazo dyes
- C09B31/12—Disazo dyes from other coupling components "C"
- C09B31/14—Heterocyclic components
- C09B31/143—1,2-Diazoles
- C09B31/147—Pyrazoles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos de tratamiento de fibrosis en un paciente, que comprende administrar a un paciente que lo necesita una cantidad terapéuticamente eficaz de un inhibidor de ACK (por ejemplo un inhibidor de BTK tal como, por ejemplo, un inhibidor de BTK irreversible, como por ejemplo ibrutinib).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086945P | 2014-12-03 | 2014-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102871A1 true AR102871A1 (es) | 2017-03-29 |
Family
ID=56092404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103925A AR102871A1 (es) | 2014-12-03 | 2015-12-01 | Métodos de tratamiento de fibrosis |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9844552B2 (es) |
| EP (1) | EP3226864A4 (es) |
| JP (1) | JP2017536397A (es) |
| CN (1) | CN106999482A (es) |
| AR (1) | AR102871A1 (es) |
| AU (1) | AU2015358503A1 (es) |
| BR (1) | BR112017011897A2 (es) |
| CA (1) | CA2968866A1 (es) |
| HK (1) | HK1244692A1 (es) |
| MX (1) | MX2017007245A (es) |
| TW (2) | TW201625257A (es) |
| WO (1) | WO2016090021A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX392373B (es) | 2013-10-25 | 2025-03-24 | Pharmacyclics Llc | Uso de ibrutinib en el tratamiento de enfermedad injerto contra huesped cronica |
| AR102871A1 (es) | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| CN113694187A (zh) * | 2021-07-20 | 2021-11-26 | 上海市东方医院（同济大学附属东方医院） | 一种用于抑制心肌纤维化的药物组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5178515B2 (ja) * | 2005-08-12 | 2013-04-10 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するピラゾール化合物 |
| PT2201840E (pt) | 2006-09-22 | 2012-02-14 | Pharmacyclics Inc | Inibidores da tirosina quinase de bruton |
| AU2009270856B2 (en) | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
| WO2011133609A2 (en) * | 2010-04-19 | 2011-10-27 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of btk inhibitors |
| ES2548414T3 (es) * | 2011-07-08 | 2015-10-16 | Novartis Ag | Novedosos derivados de pirrolo pirimidina |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| EP3033079B1 (en) | 2013-08-12 | 2018-10-31 | Pharmacyclics LLC | Methods for the treatment of her2 amplified cancer |
| MX392373B (es) | 2013-10-25 | 2025-03-24 | Pharmacyclics Llc | Uso de ibrutinib en el tratamiento de enfermedad injerto contra huesped cronica |
| TWI743019B (zh) | 2013-12-02 | 2021-10-21 | 美商製藥公司 | 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法 |
| RU2646758C2 (ru) | 2013-12-05 | 2018-03-07 | Ф. Хоффманн-Ля Рош Аг | Гетероарил пиридоны и азапиридоны с электрофильной функциональностью |
| WO2015149056A1 (en) | 2014-03-28 | 2015-10-01 | Board Of Regents, The University Of Texas System | Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury |
| AR102871A1 (es) | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
-
2015
- 2015-12-01 AR ARP150103925A patent/AR102871A1/es unknown
- 2015-12-02 CN CN201580065663.4A patent/CN106999482A/zh active Pending
- 2015-12-02 US US14/957,294 patent/US9844552B2/en active Active
- 2015-12-02 HK HK18104208.0A patent/HK1244692A1/zh unknown
- 2015-12-02 TW TW104140382A patent/TW201625257A/zh unknown
- 2015-12-02 TW TW106106688A patent/TW201740953A/zh unknown
- 2015-12-02 BR BR112017011897-1A patent/BR112017011897A2/pt not_active Application Discontinuation
- 2015-12-02 JP JP2017529401A patent/JP2017536397A/ja active Pending
- 2015-12-02 MX MX2017007245A patent/MX2017007245A/es unknown
- 2015-12-02 WO PCT/US2015/063475 patent/WO2016090021A1/en not_active Ceased
- 2015-12-02 AU AU2015358503A patent/AU2015358503A1/en not_active Abandoned
- 2015-12-02 CA CA2968866A patent/CA2968866A1/en not_active Abandoned
- 2015-12-02 EP EP15864946.7A patent/EP3226864A4/en not_active Withdrawn
-
2017
- 2017-12-08 US US15/836,482 patent/US10226466B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017011897A2 (pt) | 2018-07-03 |
| EP3226864A1 (en) | 2017-10-11 |
| TW201740953A (zh) | 2017-12-01 |
| US20180153896A1 (en) | 2018-06-07 |
| CA2968866A1 (en) | 2016-06-09 |
| CN106999482A (zh) | 2017-08-01 |
| JP2017536397A (ja) | 2017-12-07 |
| US9844552B2 (en) | 2017-12-19 |
| WO2016090021A1 (en) | 2016-06-09 |
| HK1244692A1 (zh) | 2018-08-17 |
| MX2017007245A (es) | 2018-02-16 |
| AU2015358503A1 (en) | 2017-06-08 |
| EP3226864A4 (en) | 2018-04-04 |
| US20160199376A1 (en) | 2016-07-14 |
| US10226466B2 (en) | 2019-03-12 |
| TW201625257A (zh) | 2016-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016000271A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| NI201600051A (es) | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores | |
| MX2017010773A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer. | |
| NZ730809A (en) | Methods for treating filoviridae virus infections | |
| MX2021009400A (es) | Uso de ibrutinib en el tratamiento de enfermedad injerto contra huesped cronica. | |
| PH12015502075A1 (en) | Treatment of cataplexy | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| CR20160308A (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores | |
| MX2017004471A (es) | Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística. | |
| GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| CR20160582A (es) | Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| EA201790312A1 (ru) | Комбинации лекарственных средств для лечения множественной миеломы | |
| MX375438B (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| EA201692534A1 (ru) | Способы лечения гипотонии | |
| BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
| AR102871A1 (es) | Métodos de tratamiento de fibrosis | |
| PH12014502065A1 (en) | Vesicular formulations | |
| MX382608B (es) | Tratamiento del prurito urémico. | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| MX381429B (es) | Tricostatina a (tsa) para usarse en el tratamiento del cáncer. | |
| MX2016002308A (es) | Tratamiento del mieloma multiple. | |
| MX2017003140A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| EA201690914A1 (ru) | Новое соединение для лечения тяжелой гипогликемии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |